1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Loan Repayment Program for Clinical Researchers from Disadvantaged Backgrounds (L32) is sponsored by National Institutes of Health (NIH). This program aims to recruit and retain highly qualified health professionals from disadvantaged backgrounds into clinical research careers by repaying educational loan debt. It emphasizes the need for competent health professionals from diverse backgrounds in clinical research.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Loan Repayment Program for Clinical Researchers from Disadvantaged Backgrounds (L32) | Grants & Funding U.S. Department of Health and Human Services National Institutes of Health Loan Repayment Program for Clinical Researchers from Disadvantaged Backgrounds (L32) To provide for the repayment of the educational loan debt of qualified health professionals from disadvantaged backgrounds involved in clinical research, in accordance with 42 USC 288-2(B)(1).
Qualified health professionals from disadvantaged backgrounds who contractually agree to conduct qualified clinical research are eligible to apply for this program. The objective of L32 is to recruit and retain highly qualified health professionals from disadvantaged backgrounds into clinical research careers.
The emphasis on clinical research and individuals from disadvantaged backgrounds highlights the need for the involvement of a cadre of competent health professionals in clinical research.
NIH defines Clinical Research as patient-oriented research conducted with human subjects, or research on the causes and consequences of disease in human populations involving material of human origin (such as tissue specimens and cognitive phenomena) for which an investigator or colleague directly interacts with human subjects in an outpatient or inpatient setting to clarify a problem in human physiology, pathophysiology or disease, or epidemiological or behavioral studies, outcomes or health services research, or developing new technologies, therapeutic interventions, or clinical trials.
An individual from a disadvantaged background is defined as an individual who comes from: an environment that inhibited the individual from obtaining the knowledge, skill, and ability required to enroll in and graduate from a health professions school; or comes from a family with an annual income below a level based on low-income thresholds according to family size published by the U.S. Bureau of the Census, adjusted annually for changes in the Consumer Price Index, and adjusted by the Secretary of Health and Human Services for use in all health professions programs.
The Secretary periodically publishes these income levels in the Federal Register.
An applicant must demonstrate his/her disadvantaged background status under the above definition by submitting: a written statement from the individual's former health professions school(s) that indicates that he/she qualified for Federal disadvantaged assistance during attendance; or documentation that he/she received any of the following financial aid: Health Professions Student Loans (HPSL) or Loans for Disadvantaged Student Program; or documentation that he/she received scholarships from the U.S. Department of Health and Human Services (DHHS) under the Scholarship for Individuals with Exceptional Financial Need.
Visit the Loan Repayment Programs funding category page for: LRP online application and instructions Loan Repayment Programs funding category For technical issues E-mail OER Webmaster
According to the current listing, eligibility includes: Qualified health professionals from disadvantaged backgrounds who hold a doctoral-level degree and contractually agree to conduct qualified clinical research are eligible. Applicants must be U.S. citizens, U.S. nationals, or permanent residents. Eligibility also requires a commitment to conduct research for an average of at least 20 hours per week at a domestic nonprofit or U.S. government institution, and have educational loan debt equal to at least 20% of their institutional base salary. Confirm the full requirements in the official notice before applying.
The current listing shows up to $50,000 annually. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for Loan Repayment Program for Clinical Researchers from Disadvantaged Backgrounds (L32) are due November 19, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Loan Repayment Program for Clinical Researchers from Disadvantaged Backgrounds (L32) is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article